OncoLink Cancer Treatment and Resources

Integrity of Parotid Gland Delineation for H&N IMRT: What are we sparing?



Reviewer: Voika BarAd, MD
Abramson Cancer Center of the University of Pennsylvania
Last Modified: October 19, 2005

Presenter: T.S. Hong
Presenter's Affiliation: Department of Human Oncology, University of Wisconsin Medical School, Madison, WI, Department of Medical Physics, University of Wisconsin Medical School, Madison, WI, Department of Radiology, Universi
Type of Session: Scientific

Background

  • Parotid–sparing head and neck (H&N) IMRT affords the potential to preserve salivary function and to diminish the adverse impact of chronic xerostomia on patient quality of life.
  • Although the literature provides several guidelines for H&N IMRT tumor target definition, guidelines for parotid gland delineation remain ill-defined.
  • Despite the intuitive simplicity of parotid contouring, successful execution of parotid-sparing IMRT requires accurate and consistent delineation of the parotid gland (both the superficial and deep lobes).
  • In this study, we examine the process of parotid gland contouring and assess the integrity of contouring on resultant IMRT dose reporting.

Materials and Methods

  • Comprehensive treatment plans for 50 H&N cancer patients who underwent parotid-sparing IMRT were analyzed; detailed analysis was performed with particular focus on parotid gland contouring.
  • The physician-defined parotid gland contours from original treatment plans were compared with contours that were retrospectively defined using specific neuroradiologist-defined criteria.
  • A comformality index (CI) was calculated , where perfect comformality =1, and values >1 denote decreasing overlap between contours from original treatment plans compared with contours retrospectively defined using specific neuroradiologist-defined criteria.
  • Mean dose was calculated for the total and superficial lobe of the parotid gland for physician-contoured and neuroradiologist-contoured parotid glands.

Results

  • Preliminary analysis demonstrates a mean comformality index of 1.26 when comparing H&N IMRT of original treatment plans with contours retrospectively defined using specific neuroradiologist-defined criteria.
  • The most common contour variations were a result of failure to appreciate an accessory parotid gland, inaccurate definition of the deep parotid lobe, or suboptimal CT window settings, particularly from images associated with significant dental artifact.
  • Mean parotid gland dose from IMRT plans varied significantly based on inclusion or exclusion of the deep lobe in dose calculations; these distinctions introduced a 2-4 Gy variation in the mean parotid gland lobe.

Author's Conclusions

  • Accurate delineation of parotid glands requires careful attention to anatomic detail and can significantly impact calculated mean dose to "spared" parotid glands in H&N planning.
  • Several simple educational tips can improve the integrity of parotid gland contouring by radiation oncologists.

Clinical/Scientific Implications

  • Detailed parotid gland contouring is seldom reported in the literature.
  • Contouring parotid structure may influence the mean dose to the superficial lobe and total parotid gland.
  • Attention to properly defining parotid gland contours represents a critical part of xerostomia prevention during IMRT H&N treatment, and can influence the accuracy and interpretation of the parotid doses reported in the IMRT literature.

OncoLink I wish u knew...

Dr. Giantonio discusses the privileges bestowed on physicians in our society and the dangers of this. Read more.

Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet

Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy

Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies

Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer

Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults

OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews


Ask the Experts
Brown Bag Chat
Tracy's Corner

About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement

OncoLink Cancer Resources RSS What's New RSS